Navigation Links
UC Davis doctors use multimedia to increase colorectal cancer screening among Hispanics
Date:9/15/2008

cussions about cancer are initiated and decisions about screening are solidified.

"One of the major differences in this software program is that it is offered right in the patients' own doctors' offices when they are already thinking about health and have time to talk with their physicians," said Jerant. "This makes it even more likely that they will use the information to ask about screening and discuss recommendations."

Data from the study, to be launched this month, will be collected over the course of four-and-a-half years. Information from Hispanic patients will be compared to information from non-Hispanic white patients to determine if the software helps improve participation in screening overall and, specifically, if it helps reduce or eliminate disparities in screening between these groups. If shown to be effective, the software could eventually be made available to physician offices nationwide.

Excluding skin cancers, colorectal cancer is the third-most common cancer diagnosed in both men and women in the United States. The American Cancer Society estimates that 108,070 new cases of colon cancer and 40,740 new cases of rectal cancer will be diagnosed in 2008. Screening can reduce those numbers by identifying increased cancer risks and, in the case of colonoscopy, actually removing polyps before they become cancerous. Hispanics are less likely than non-Hispanics to report receiving screening tests for colorectal cancer, making it a critical priority to develop and evaluate interventions that reduce or even eliminate this disparity.


'/>"/>

Contact: Karen Finney
karen.finney@ucdmc.ucdavis.edu
916-734-9064
University of California - Davis - Health System
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Davis Vision, United Way 2-1-1 and the United Auto Workers Team Up to Provide Free Vision Screenings August 25 for Detroit Children
2. Texas State Rep. John Davis Honored as Champion for Children by The AMERIGROUP Foundation
3. Cline Davis & Mann Launches Platform Advisors(TM), a New Division to Provide Integrated Strategic and Scientific Consulting Services for the Pharmaceutical, Biotechnology, and Medical Device Industry
4. J. Greg Davis Appointed President & Chief Executive Officer of Tryton Medical, Inc.
5. NCRA Urges U.S. Reps. Danny Davis and Judy Biggert to Approve in Conference the Higher Education Reauthorization Bill Providing Closed Captioning for 30 Million Deaf and Hard-of-Hearing Americans
6. Boston Kids Enjoy Free Davis Vision Screenings
7. Davis Vision, United Concordia Free Clinic Promotes Childrens Eye and Dental Health
8. TeamStaff Hires Jeff Davis as Director of Operations for Government Solutions Subsidiary
9. Sex & the City Gets Serious About HIV and AIDS in South Africa - Kristin Davis Helps Oxfam Break the Stigma and Close the Treatment Gaps Fuelling AIDS
10. Congressman Davis to Tour Pathology Laboratory, Learn Critical Role in Patient Care
11. New UC Davis study finds physician style and HMO affiliation impact lengths of patient visit
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Hear Indiana Announces Talk*Walk*Run 2008 2Health News:Hear Indiana Announces Talk*Walk*Run 2008 3Health News:USDA Grants Organic Certification to Ayala's Herbal Water(TM) 2Health News:Prevention and control of childhood pneumonia: Bulletin of the World Health Organization 2Health News:Thermage, a Leading Aesthetic Medical Device Company, Announces First Time Exhibitor Status at ACOG Meeting 2Health News:Thermage, a Leading Aesthetic Medical Device Company, Announces First Time Exhibitor Status at ACOG Meeting 3Health News:AVEENO(R) Announces Sponsorship and Kick-Off of The Skin Cancer Foundation's 'Road to Healthy Skin Tour' Presented by AVEENO(R) and Rite Aid 2Health News:AVEENO(R) Announces Sponsorship and Kick-Off of The Skin Cancer Foundation's 'Road to Healthy Skin Tour' Presented by AVEENO(R) and Rite Aid 3Health News:CNS Response, Inc: rEEG(R) Research to be Presented at 38th National Council Conference 2Health News:CNS Response, Inc: rEEG(R) Research to be Presented at 38th National Council Conference 3
Breaking Medicine Technology:The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8Watson Confirms Filing of Abbreviated New Drug Application for Generic Sanctura XR 28R 29 51761 1Watson Confirms Filing of Abbreviated New Drug Application for Generic Sanctura XR 28R 29 51761 2Menopause Is More Than A Hot Flash 51759 1Menopause Is More Than A Hot Flash 51759 2Menopause Is More Than A Hot Flash 51759 3Menopause Is More Than A Hot Flash 51759 4Intravenous Immune Biologics Will Suffer from the Pending Shift in Coverage from the Medical to the Pharmacy Benefit 51757 1Intravenous Immune Biologics Will Suffer from the Pending Shift in Coverage from the Medical to the Pharmacy Benefit 51757 2Intravenous Immune Biologics Will Suffer from the Pending Shift in Coverage from the Medical to the Pharmacy Benefit 51757 3